格隆汇12月4日｜安科生物公告，公司参股公司博生吉医药科技（苏州）有限公司、博生吉安科细胞技 术有限公司自主研发的PA3-17注射液新增"针对儿童和青少年复发/难治性T淋巴母细胞白血病/淋巴瘤 （R/RT-ALL/LBL）"的适应症临床试验申请已获受理。本次新增适应症临床试验申请获得受理仅是新药 研发的阶段性成果，能否获得国家药品监督管理局批准进行临床试验、上市尚存在不确定性，敬请广大 投资者谨慎决策，注意防范投资风险。 ...

安科生物公告，参股公司博生吉医药科技（苏州）有限公司、博生吉安科细胞技术有限公司自主研发的 PA3-17注射液新增"针对儿童和青少年复发/难治性T淋巴母细胞白血病/淋巴瘤（R/RT-ALL/LBL）"的适 应症临床试验申请已获受理，并收到国家药品监督管理局行政许可文书《受理通知书》，受理号为： CXSL2501040。 ...

本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 近日，安徽安科生物工程（集团）股份有限公司（以下简称"公司"）参股 公司博生吉医药科技（苏州）有限公司、博生吉安科细胞技术有限公司（以下简 称"博生吉安科"）自主研发的PA3-17注射液新增"针对儿童和青少年复发/难 治性T淋巴母细胞白血病/淋巴瘤（R/R T-ALL/LBL）"的适应症临床试验申请已 获受理，并收到国家药品监督管理局行政许可文书《受理通知书》，受理号为： CXSL2501040。具体情况如下： PA3-17注射液是博生吉安科自主研发的全球首款获得新药临床试验批准的 靶向CD7的自体CAR-T细胞治疗产品，已于2025年8月被国家药品监督管理局药 品审评中心（CDE）纳入突破性治疗品种名单。该产品目前正在开展针对成人复 发/难治性T淋巴母细胞白血病/淋巴瘤（R/R T-ALL/LBL）患者的关键性II期临床 试验，具体内容详见公司于巨潮资讯网披露的《关于参股公司PA3-17注射液获准 进入关键性II期临床试验的公告》（公告编号：2025-051）。 本次为PA3-17注射液新增用于儿童和青少年复发/难 ...

Core Viewpoint - Anke Biological has experienced a decline in stock price recently, with a year-to-date increase of 15% but a notable drop in the last 20 and 60 days [1][2] Financial Performance - For the period from January to September 2025, Anke Biological reported a revenue of 1.963 billion yuan, representing a year-on-year growth of 2.15%. However, the net profit attributable to shareholders decreased by 6.48% to 551 million yuan [2] - The company has distributed a total of 2.662 billion yuan in dividends since its A-share listing, with 1.252 billion yuan distributed in the last three years [3] Stock Market Activity - As of December 3, Anke Biological's stock price was 9.65 yuan per share, with a market capitalization of 16.14 billion yuan. The stock has seen a trading volume of 155 million yuan and a turnover rate of 1.31% [1] - The stock has been on the "龙虎榜" (a list of stocks with significant trading activity) once this year, with a net purchase of 193 million yuan on July 31 [1] Shareholder Information - As of November 10, the number of shareholders for Anke Biological was 76,100, a decrease of 1.10% from the previous period. The average number of circulating shares per shareholder increased by 1.11% to 16,062 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and several investment funds, with notable changes in their holdings [3]

证券日报网讯 12月2日晚间，安科生物发布公告称，本次申请解除限售的抗肿瘤事业部预留授予激励对 象共19名，申请解除限售的第一类限制性股票数量为372，750股，占公司目前股本总额1，672，521， 258股的0.0223%，本次解除限售的限制性股票上市流通日为2025年12月5日。 （文章来源：证券日报） ...

证券代码：300009 证券简称：安科生物 公告编号：2025-073 安徽安科生物工程(集团)股份有限公司 关于第三期限制性股票激励计划抗肿瘤事业部获授人员预留授予 股票第一个解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 重要内容提示： 安徽安科生物工程（集团）股份有限公司（以下简称"公司"） 于 2025 年 11 月 24 日召开了第八届董事会第二十四次会议、第八届监事会第二十二次会议，审 议通过了《关于第三期限制性股票激励计划抗肿瘤事业部获授人员首次授予股票第 一个解除限售期解除限售条件成就及预留授予股票第一个解除限售期解除限售条 件部分成就的议案》，同意按照《公司第三期限制性股票激励计划（草案修订稿）》 （以下简称"《第三期激励计划》"）的相关规定以及公司 2022 年第二次临时股 东大会的授权，对满足解除限售条件的激励对象办理解除限售事宜。本次解除限售 的具体情况如下： 一、第三期激励计划实施情况简述 1、2022 年 8 月 24 日，公司召开第七届董事会第二十二次会议及第七届监事会 第十九次会议，审议通 ...

证券代码：300009 证券简称：安科生物 公告编号：2025-071 安徽安科生物工程(集团)股份有限公司 关于第三期限制性股票激励计划抗肿瘤事业部以外获授人员首次 授予股票第三个解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 重要内容提示： 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）于 2025 年 11 月 24 日召开了第八届董事会第二十四次会议、第八届监事会第二十二次会议，审 议通过了《关于第三期限制性股票激励计划抗肿瘤事业部以外获授人员首次授予股 票第三个解除限售期解除限售条件成就的议案》，同意按照《公司第三期限制性股 票激励计划（草案修订稿）》（以下简称"《第三期激励计划》"）的相关规定以及公 司 2022 年第二次临时股东大会的授权，对满足解除限售条件的激励对象办理解除 限售事宜。本次解除限售的具体情况如下： 一、第三期激励计划实施情况简述 1、2022 年 8 月 24 日，公司召开第七届董事会第二十二次会议及第七届监事会 第十九次会议，审议通过了《关于<公司第三期限制性股票激励计划（草案 ...

证券代码：300009 证券简称：安科生物 公告编号：2025-072 安徽安科生物工程(集团)股份有限公司 关于第三期限制性股票激励计划抗肿瘤事业部获授人员首次授予 股票第一个解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 重要内容提示： 安徽安科生物工程（集团）股份有限公司（以下简称"公司"） 于 2025 年 11 月 24 日召开了第八届董事会第二十四次会议、第八届监事会第二十二次会议，审 议通过了《关于第三期限制性股票激励计划抗肿瘤事业部获授人员首次授予股票第 一个解除限售期解除限售条件成就及预留授予股票第一个解除限售期解除限售条 件部分成就的议案》，同意按照《公司第三期限制性股票激励计划（草案修订稿）》 （以下简称"《第三期激励计划》"）的相关规定以及公司 2022 年第二次临时股 东大会的授权，对满足解除限售条件的激励对象办理解除限售事宜。本次解除限售 的具体情况如下： 一、第三期激励计划实施情况简述 1、2022 年 8 月 24 日，公司召开第七届董事会第二十二次会议及第七届监事会 第十九次会议，审议通 ...

Company Overview - Baoji Pharmaceutical is set to launch an IPO from December 2 to December 5, 2025, offering 37.9117 million shares, with 10% allocated for Hong Kong and 90% for international sales. The maximum public offering price is HKD 26.38 per share, with an entry fee of approximately HKD 2,664, and shares are expected to begin trading on December 10, 2025 [1] - The company has attracted significant investment, with a total funding exceeding CNY 1.5 billion from various investors, including local industry capital and market-oriented funds, resulting in a post-investment valuation of approximately CNY 4.87 billion, which is 23 times the initial post-investment valuation [1] Investment and Partnerships - The IPO has secured a strong cornerstone investor lineup, including well-known institutions such as Anke Bio, DC Alpha SPC, and Guotai Junan Securities, with a total subscription of HKD 200.6 million, accounting for about 21.77% of the total fundraising [2] - The presence of cornerstone investors highlights market recognition of the company's technological capabilities and commercial potential, providing a solid foundation for the smooth progress of the issuance [2] Product Pipeline and Technology - Baoji Pharmaceutical focuses on four key areas: antibody-mediated autoimmune diseases, large-volume subcutaneous injections, reproductive medicine drugs, and transformative products replacing traditional biochemical extraction methods. The company has developed a robust pipeline with seven clinical-stage candidates and seven preclinical candidates [2] - The core pipeline includes KJ017, a recombinant hyaluronidase for large-volume subcutaneous delivery, which is currently under review for market approval; KJ103, an IgG degrading enzyme in Phase III clinical trials for autoimmune diseases; and SJ02, the first long-acting follicle-stimulating hormone approved in China, which received approval in August [3] Commercialization and Market Position - The commercialization of the hyaluronidase technology has led to partnerships with several antibody drug companies, and an exclusive sales agency agreement with Anke Bio for SJ02 in Greater China has been established [3] - The focus on large-volume subcutaneous injection technology positions Baoji Pharmaceutical as a key player in the biopharmaceutical sector, offering advantages over traditional intravenous administration by reducing adverse events and significantly shortening administration time from 30-180 minutes to 2-5 minutes [3] Industry Landscape - Halozyme is identified as a leading company in the global hyaluronidase subcutaneous injection technology, with its technology applied to several major antibody drugs. The trend of developing subcutaneous versions of various drugs, including oncology treatments, is gaining momentum [4] - Baoji Pharmaceutical aims to become the "Halozyme of China," leveraging its expertise in hyaluronidase technology and core pipeline to empower its products and assist other domestic antibody drugs in achieving subcutaneous delivery upgrades, thereby capturing a significant market position in the biopharmaceutical innovation wave [4]

Group 1 - The company, Baoji Pharmaceutical-B (02659.HK), plans to globally offer 37.9117 million H-shares, with 3.7912 million shares available in Hong Kong and 34.1205 million shares for international distribution, subject to reallocation [1] - The offering price is set at HKD 26.38 per share, with a trading unit of 100 shares, and the shares are expected to commence trading on the Hong Kong Stock Exchange on December 10, 2025 [1] Group 2 - The company, established in 2019, focuses on four strategic areas: large-volume subcutaneous delivery, antibody-mediated autoimmune diseases, assisted reproduction, and recombinant biopharmaceuticals [2] - The pipeline includes 12 self-developed products, with three core products: SJ02 (a long-acting recombinant human follicle-stimulating hormone), KJ017 (a recombinant hyaluronidase), and KJ103 (an innovative recombinant immunoglobulin G degrading enzyme) [2] Group 3 - The company has entered into cornerstone investment agreements, with cornerstone investors agreeing to subscribe for shares totaling HKD 200.6 million, which equates to approximately 7.6041 million shares at the offering price [3] - The net proceeds from the global offering are expected to be approximately HKD 921.5 million, with allocations of 53.5% for R&D and commercialization of core products, 17.7% for advancing other pipeline products, 8.4% for optimizing the proprietary synthetic biology platform, 10.4% for enhancing production capacity, and 10.0% for working capital and general corporate purposes [3]